“…Some of these strategies include conformational shielding with bulky lipophilic groups, amide bond modifications, inducing IMHBs, and macrocyclization . Certain polar bRo5 compounds, like PROTACs, saquinavir, atazanavir, and ritonavir, can display adaptability between elongated forms in aqueous environments and compact, less polar shapes in nonpolar solvents due to IMHB-induced chameleonicity. ,,, This behavior, evident in simulations ,, and column-based studies, facilitates solubility and permeability. Some compounds, such as rifampicin, leverage static IMHB for polarity reduction, whereas molecules like paritaprevir and cyclosporin A combine both shielding and IMHBs.…”